News for Cannara Biotech Inc. (LOVE.CN)

Cannara Biotech Inc. (OTCQB: LOVFF) will release its fiscal Q3 2025 financial results on July 28, 2025. The results for the quarter ending May 31, 2025,

MONTREAL, July 21, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (”œCannara”, ”œthe Company”, ”œus” or ”œwe”) (TSXV: LOVE) ( LOVFF) (FRA: 8CB0), a

MONTREAL, July 21, 2025 (GLOBE NEWSWIRE) —

Cannara Biotech (LOVFF) to host an investor webcast on June 25, 2025, at 2:00 PM ET. CFO Nicholas Sosiak will present key aspects of the company's busin

MONTREAL, June 19, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (”œCannara”, ”œthe Company”, ”œus” or ”œwe”) (TSXV: LOVE) ( LOVFF) (FRA: 8CB0), a

**media[659376]**

Cannara, under the stock ticker LOVFF, has effectively repaid $1 million toward its outstanding convertible debenture. This debt was originally issued on June 2

Release Date: April 29, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Cannara Biotech

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NLOVE.V - Cannara Biotech IncQ2 2025 Cannara Biotech Inc Earnings CallApr 29, 2025 / 03:00PM GM

Cannara Biotech Inc. (OTCQB:LOVFF) Q2 2025 Earnings Conference Call April 29, 2024 11:00 AM ETCompany ParticipantsScott Carroll - VP Commercial Strategy...

Cannara Biotech Inc. (LOVFF) reported a significant financial milestone for the second quarter of 2025, with net revenues reaching C$26.6 million. This reflects

Record Revenue: Net revenues of $26.6 million in Q2 2025, a 35% increase compared to $19.7 million in Q2 2024, driven by national brand growth and product innov

\n Cannara Biotech (TSXV: LOVE) (OTCQB: LOVFF) to release Q2 2025 financial results on April 28, 2025. Investors can participate in an earn

MONTREAL, April 16, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (â\u0080\u009cCannaraâ\u0080\u009d, â\u0080\u009cthe Companyâ\u0080\u009d, â\u0080\u009cusâ\u0080\u009d or â\u0080\u009cweâ\u0080\u009d) (TSXV: LOVE) ( LOVFF) (FRA: 8CB0),

**media[596622]**

**media[574693]**

**media[559080]**

**media[548533]**

MONTREAL, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (”œCannara”, ”œthe Company”, ”œus” or ”œwe”) (TSXV: LOVE) ( LOVFF) (FRA: 8CB0), a